July 29 – Shenzhen Hepalink Pharmaceutical (002399) recorded a 39.51-percent year-on-year fall in preliminary net profits during the first half of 2011 to 362 million yuan, reports China Business News, citing a company filing. Sales revenues fell 13 percent year-on-year to 1.57 billion yuan while earnings per share hit 0.45 yuan, a decrease of 43.75 percent.

Poor earnings from sales were blamed on lower selling prices, and the firm attributed the decrease in net profits to the way it calculates raw material costs.

Hepalink posted a 40-percent year-on-year fall in net profits during the first quarter.

Since the third quarter of 2010, domestic heparin products suffered from rising costs and falling selling prices.

Hepalink was founded in 1998 in Shenzhen and produces heparin sodium crude pharmaceutical drugs. Almost all of its products are exported.